CA2108374A1 - Quick-dissolution solid preparation - Google Patents

Quick-dissolution solid preparation

Info

Publication number
CA2108374A1
CA2108374A1 CA002108374A CA2108374A CA2108374A1 CA 2108374 A1 CA2108374 A1 CA 2108374A1 CA 002108374 A CA002108374 A CA 002108374A CA 2108374 A CA2108374 A CA 2108374A CA 2108374 A1 CA2108374 A1 CA 2108374A1
Authority
CA
Canada
Prior art keywords
drug
dissolution
quick
solid preparation
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002108374A
Other languages
English (en)
French (fr)
Inventor
Katsuhiko Yano
Yasuhiro Nishizono
Shigeru Yamazaki
Tadayoshi Ohmura
Shunji Hasumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2108374A1 publication Critical patent/CA2108374A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug

Landscapes

  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002108374A 1991-04-15 1992-04-14 Quick-dissolution solid preparation Abandoned CA2108374A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10989691 1991-04-15
JPHEI3-109896 1991-04-15

Publications (1)

Publication Number Publication Date
CA2108374A1 true CA2108374A1 (en) 1992-10-16

Family

ID=14521910

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002108374A Abandoned CA2108374A1 (en) 1991-04-15 1992-04-14 Quick-dissolution solid preparation

Country Status (8)

Country Link
US (1) US5624687A (enExample)
EP (1) EP0580862A4 (enExample)
KR (1) KR0179343B1 (enExample)
AU (1) AU1644092A (enExample)
CA (1) CA2108374A1 (enExample)
HU (1) HUT67388A (enExample)
TW (1) TW212139B (enExample)
WO (1) WO1992018109A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6141260A (en) 1998-08-27 2000-10-31 Micron Technology, Inc. Single electron resistor memory device and method for use thereof
ES2310164T3 (es) * 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6569686B2 (en) * 2000-01-28 2003-05-27 Pion, Inc. Measurement of solubility-pH profiles
GB0012448D0 (en) 2000-05-24 2000-07-12 Astrazeneca Ab New process
GB0104752D0 (en) * 2001-02-27 2001-04-18 Astrazeneca Ab Pharmaceutical compositions
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
WO2005065317A2 (en) 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
NZ548215A (en) * 2003-12-31 2009-08-28 Cima Labs Inc Effervescent oral opiate dosage form
KR101184138B1 (ko) * 2003-12-31 2012-09-19 시마 랩스 인크. 일반적인 선형 발포성 경구 펜타닐 투약 제형 및 투여 방법
KR100539706B1 (ko) * 2005-01-25 2005-12-28 지엘팜텍 주식회사 타크로리무스 및 장용성 고분자를 함유하는 고체분산체
US8861813B2 (en) * 2008-03-13 2014-10-14 Mallinckrodt Llc Multi-function, foot-activated controller for imaging system
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
EP3824296B1 (en) 2018-07-20 2026-04-01 Lipocine Inc. Oral pharmaceutical composition comprising testosterone tridecanoate and/or testosterone dodecanoate for treating liver diseases
WO2023130119A1 (en) 2022-01-03 2023-07-06 Engrail Therapeutics, Inc. Deuterated organic compounds and uses thereof
WO2025010255A2 (en) 2023-07-02 2025-01-09 Engrail Therapeutics, Inc. Deuterated organic compounds and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5840529B2 (ja) * 1975-09-29 1983-09-06 明治製菓株式会社 ケイコウヨウセイザイノセイホウ
SE426548B (sv) * 1978-12-05 1983-01-31 Haessle Ab Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS5649314A (en) * 1979-07-05 1981-05-02 Yamanouchi Pharmaceut Co Ltd Lasting pharmaceutical composition having prolonged action and its preparation
JPS58116414A (ja) * 1981-12-23 1983-07-11 Yamanouchi Pharmaceut Co Ltd ニカルジピン持続性製剤用球形顆粒およびその製造法
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JP2528706B2 (ja) * 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
IL92343A0 (en) * 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
DE3900811A1 (de) * 1989-01-13 1990-07-19 Kali Chemie Pharma Gmbh Neue arzneiform
JPH0729926B2 (ja) * 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
IL95423A (en) * 1989-09-21 1994-11-11 American Cyanamid Co Pulsatile once-a-day delivery systems for minocycline
US5223268A (en) * 1991-05-16 1993-06-29 Sterling Drug, Inc. Low solubility drug-coated bead compositions
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions

Also Published As

Publication number Publication date
AU1644092A (en) 1992-11-17
HUT67388A (en) 1995-04-28
WO1992018109A1 (en) 1992-10-29
EP0580862A1 (en) 1994-02-02
HU9302927D0 (en) 1993-12-28
KR0179343B1 (ko) 1999-03-20
US5624687A (en) 1997-04-29
EP0580862A4 (en) 1995-04-26
TW212139B (enExample) 1993-09-01

Similar Documents

Publication Publication Date Title
US5624687A (en) Quick-dissolution solid preparation
US6531153B2 (en) Composition with sustained release of levodopa and carbidopa
EP0533297B1 (en) Controlled-release pharmaceutical formulations
US5525354A (en) Pharmaceutical preparation and process for its manufacture
EP0069097B1 (en) Pharmaceutical mixture
CA1338889C (en) Morphine containing composition
KR910004595B1 (ko) 작용 지속형 피나시딜 제제의 제조방법
US20020098227A1 (en) Process for manufacturing coated granules with masked taste and immediate release of the active principle
JPH07145052A (ja) 良好な溶解特性を有する医薬組成物
EP0221732A2 (en) Sustained release tablets
IL106477A (en) Controlled release morphine salt preparations
EP1291014A1 (en) A process for producing a pharmaceutical solid preparation containing a poorly soluble drug
KR19980702370A (ko) 염기성 물질로 안정화된 약제학적 조성물
KR910002670B1 (ko) 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법
EP0386967A3 (en) A drug-release controlling coating material for long acting formulations
EP0571973B1 (en) Slow-release sodium valproate tablets
JP2003528905A (ja) スタブジン含有持続放出性ビーズ剤
JPWO1997033574A1 (ja) バルプロ酸金属塩の徐放性錠剤
US5445830A (en) Highly absorbable pharmaceutical composition
EP0410422A2 (en) A highly absorbable pharmaceutical composition
TWI286072B (en) Sleeping medicine formed by coating solid
Nimmerfall et al. Dependence of area under the curve on proquazone particle size and in vitro dissolution rate
JP2939069B2 (ja) ニカルジピン持続性製剤とその製造方法
EP0371683B1 (en) Controlled release flecainide acetate formulation
Melia et al. mechanisms of drug release from tablets and capsules. 2. Dissolution

Legal Events

Date Code Title Description
FZDE Discontinued